Literature DB >> 19702883

Type IIb von Willebrand disease with angiodysplasias and refractory gastrointestinal bleeding successfully treated with thalidomide.

E Nomikou, V Tsevrenis, A Gafou, M Bellia, G Theodossiades.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19702883     DOI: 10.1111/j.1365-2516.2009.02085.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


× No keyword cloud information.
  8 in total

Review 1.  Angiodysplasia in von Willebrand Disease: Understanding the Clinical and Basic Science.

Authors:  Soundarya Selvam; Paula James
Journal:  Semin Thromb Hemost       Date:  2017-05-05       Impact factor: 4.180

2.  New therapies for von Willebrand disease.

Authors:  Pier Mannuccio Mannucci
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

3.  The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development.

Authors:  Waqas Rehman; Lisa M Arfons; Hillard M Lazarus
Journal:  Ther Adv Hematol       Date:  2011-10

Review 4.  Emerging role of thalidomide in the treatment of gastrointestinal bleeding.

Authors:  Michael McFarlane; Lauren O'Flynn; Rachel Ventre; Benjamin R Disney
Journal:  Frontline Gastroenterol       Date:  2017-11-02

5.  New therapies for von Willebrand disease.

Authors:  Pier Mannuccio Mannucci
Journal:  Blood Adv       Date:  2019-11-12

Review 6.  von Willebrand factor regulation of blood vessel formation.

Authors:  Anna M Randi; Koval E Smith; Giancarlo Castaman
Journal:  Blood       Date:  2018-06-04       Impact factor: 22.113

7.  Recombinant von Willebrand factor for severe gastrointestinal bleeding unresponsive to other treatments in a patient with type 2A von Willebrand disease: a case report.

Authors:  Racquel Brown
Journal:  Blood Coagul Fibrinolysis       Date:  2017-10       Impact factor: 1.276

Review 8.  Von Willebrand factor, angiodysplasia and angiogenesis.

Authors:  Anna M Randi; Mike A Laffan; Richard D Starke
Journal:  Mediterr J Hematol Infect Dis       Date:  2013-09-02       Impact factor: 2.576

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.